Low-dose aspirin confers a survival benefit in patients with pathological advanced-stage oral squamous cell carcinoma

Abstract Oral squamous cell carcinoma (OSCC) remains one of the most challenging clinical problems in the field due to its high rate of locoregional and distant metastases. However, studies that assess the association between aspirin use and survival in patients with OSCC are limited. Moreover, pati...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sheng-Dean Luo, Shao-Chun Wu, Wei-Chih Chen, Ching-Nung Wu, Tai-Jan Chiu, Yao-Hsu Yang, Shau-Hsuan Li, Fu-Min Fang, Tai-Lin Huang, Chang-Chun Hsiao, Chang-Han Chen
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/5402fd33797f41dea3bf84e48b122b74
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5402fd33797f41dea3bf84e48b122b74
record_format	dspace
spelling	oai:doaj.org-article:5402fd33797f41dea3bf84e48b122b742021-12-02T19:02:30ZLow-dose aspirin confers a survival benefit in patients with pathological advanced-stage oral squamous cell carcinoma10.1038/s41598-021-96614-y2045-2322https://doaj.org/article/5402fd33797f41dea3bf84e48b122b742021-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-96614-yhttps://doaj.org/toc/2045-2322Abstract Oral squamous cell carcinoma (OSCC) remains one of the most challenging clinical problems in the field due to its high rate of locoregional and distant metastases. However, studies that assess the association between aspirin use and survival in patients with OSCC are limited. Moreover, patients that recruited from those studies might have tumors that arose from different anatomic regions of the head and neck, including the oral cavity, oropharynx, etc. Since tumors within these distinct anatomic regions are unique in the context of epidemiology and tumor progression, we sought to evaluate the association of aspirin use with squamous cell carcinomas located within the oral cavity only. In this 10-year cohort study, we evaluated aspirin use and survival rates in relation to clinical characteristics as well as duration of aspirin use in patients with OSCC. Our findings suggest that OSCC patients with aspirin use for more than 180 days showed improved overall and disease-specific survival rates. Aspirin also improves survival in patients across various stages of OSCC. Cox regression models indicated that aspirin use was associated with a good prognosis. In conclusion, this evidence indicates that aspirin may be potentially used as an adjuvant therapy for OSCC.Sheng-Dean LuoShao-Chun WuWei-Chih ChenChing-Nung WuTai-Jan ChiuYao-Hsu YangShau-Hsuan LiFu-Min FangTai-Lin HuangChang-Chun HsiaoChang-Han ChenNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Sheng-Dean Luo Shao-Chun Wu Wei-Chih Chen Ching-Nung Wu Tai-Jan Chiu Yao-Hsu Yang Shau-Hsuan Li Fu-Min Fang Tai-Lin Huang Chang-Chun Hsiao Chang-Han Chen Low-dose aspirin confers a survival benefit in patients with pathological advanced-stage oral squamous cell carcinoma
description	Abstract Oral squamous cell carcinoma (OSCC) remains one of the most challenging clinical problems in the field due to its high rate of locoregional and distant metastases. However, studies that assess the association between aspirin use and survival in patients with OSCC are limited. Moreover, patients that recruited from those studies might have tumors that arose from different anatomic regions of the head and neck, including the oral cavity, oropharynx, etc. Since tumors within these distinct anatomic regions are unique in the context of epidemiology and tumor progression, we sought to evaluate the association of aspirin use with squamous cell carcinomas located within the oral cavity only. In this 10-year cohort study, we evaluated aspirin use and survival rates in relation to clinical characteristics as well as duration of aspirin use in patients with OSCC. Our findings suggest that OSCC patients with aspirin use for more than 180 days showed improved overall and disease-specific survival rates. Aspirin also improves survival in patients across various stages of OSCC. Cox regression models indicated that aspirin use was associated with a good prognosis. In conclusion, this evidence indicates that aspirin may be potentially used as an adjuvant therapy for OSCC.
format	article
author	Sheng-Dean Luo Shao-Chun Wu Wei-Chih Chen Ching-Nung Wu Tai-Jan Chiu Yao-Hsu Yang Shau-Hsuan Li Fu-Min Fang Tai-Lin Huang Chang-Chun Hsiao Chang-Han Chen
author_facet	Sheng-Dean Luo Shao-Chun Wu Wei-Chih Chen Ching-Nung Wu Tai-Jan Chiu Yao-Hsu Yang Shau-Hsuan Li Fu-Min Fang Tai-Lin Huang Chang-Chun Hsiao Chang-Han Chen
author_sort	Sheng-Dean Luo
title	Low-dose aspirin confers a survival benefit in patients with pathological advanced-stage oral squamous cell carcinoma
title_short	Low-dose aspirin confers a survival benefit in patients with pathological advanced-stage oral squamous cell carcinoma
title_full	Low-dose aspirin confers a survival benefit in patients with pathological advanced-stage oral squamous cell carcinoma
title_fullStr	Low-dose aspirin confers a survival benefit in patients with pathological advanced-stage oral squamous cell carcinoma
title_full_unstemmed	Low-dose aspirin confers a survival benefit in patients with pathological advanced-stage oral squamous cell carcinoma
title_sort	low-dose aspirin confers a survival benefit in patients with pathological advanced-stage oral squamous cell carcinoma
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/5402fd33797f41dea3bf84e48b122b74
work_keys_str_mv	AT shengdeanluo lowdoseaspirinconfersasurvivalbenefitinpatientswithpathologicaladvancedstageoralsquamouscellcarcinoma AT shaochunwu lowdoseaspirinconfersasurvivalbenefitinpatientswithpathologicaladvancedstageoralsquamouscellcarcinoma AT weichihchen lowdoseaspirinconfersasurvivalbenefitinpatientswithpathologicaladvancedstageoralsquamouscellcarcinoma AT chingnungwu lowdoseaspirinconfersasurvivalbenefitinpatientswithpathologicaladvancedstageoralsquamouscellcarcinoma AT taijanchiu lowdoseaspirinconfersasurvivalbenefitinpatientswithpathologicaladvancedstageoralsquamouscellcarcinoma AT yaohsuyang lowdoseaspirinconfersasurvivalbenefitinpatientswithpathologicaladvancedstageoralsquamouscellcarcinoma AT shauhsuanli lowdoseaspirinconfersasurvivalbenefitinpatientswithpathologicaladvancedstageoralsquamouscellcarcinoma AT fuminfang lowdoseaspirinconfersasurvivalbenefitinpatientswithpathologicaladvancedstageoralsquamouscellcarcinoma AT tailinhuang lowdoseaspirinconfersasurvivalbenefitinpatientswithpathologicaladvancedstageoralsquamouscellcarcinoma AT changchunhsiao lowdoseaspirinconfersasurvivalbenefitinpatientswithpathologicaladvancedstageoralsquamouscellcarcinoma AT changhanchen lowdoseaspirinconfersasurvivalbenefitinpatientswithpathologicaladvancedstageoralsquamouscellcarcinoma
_version_	1718377264509353984

Low-dose aspirin confers a survival benefit in patients with pathological advanced-stage oral squamous cell carcinoma

Ejemplares similares